Clinical Implications of the Contrasting Effects of In Vivo Thrombin Receptor Activation (Protease-Activated Receptor Type 1) on the Human Vasculature**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 51, Issue 18, 2008, Pages 1757-1759

  Cleator, John H ^a   Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; FIBRINOGEN; G PROTEIN COUPLED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; SCH 530348; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

AMINO TERMINAL SEQUENCE; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOSIS; VASCULARIZATION;

ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE, SMOOTH; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; THROMBIN; VASOCONSTRICTION; VASODILATION;

EID: 43049146222     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.01.037     Document Type: Editorial

References (23)

1. Jamieson G.A. Pathophysiology of platelet thrombin receptors. Thromb Haemost 78 (1997) 242-246
2. Coughlin S.R. Thrombin signaling and protease-activated receptors. Nature 407 (2000) 258-264
3. Vu T.K., Hung D.T., Wheaton V.I., and Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 (1991) 1057-1068
4. Scarborough R.M., Naughton M.A., Teng W., et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 267 (1992) 13146-13149
5. Coughlin S.R., Vu T.K., Hung D.T., and Wheaton V.I. Expression cloning and characterization of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Semin Thromb Haemost 18 (1992) 161-166
6. De Mey J.G., Claeys M., and Vanhoutte P.M. Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J Pharmacol Exp Ther 222 (1982) 166-173
7. Gebremedhin D., Ballagi-Pordany G., Hadhazy P., Magyar K., and Machovich R. Species specificity of thrombin-induced changes in vascular tone. Eur J Pharmacol 132 (1986) 71-74
8. Gudmundsdottir I.J., Megson I.L., Kell J.S., et al. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans. Circulation 114 (2006) 1625-1632
9. Gu{A figure is presented}mundsdóttir I.J., Lang N.N., Boon N.A., et al. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol 51 (2008) 1749-1756
10. Matsushita K., Morrell C.N., Cambien B., et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115 (2003) 139-150
11. McEver R.P., Beckstead J.H., Moore K.L., Marshall-Carlson L., and Bainton D.F. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 84 (1989) 92-99
12. Hattori R., Hamilton K.K., Fugate R.D., McEver R.P., and Sims P.J. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 264 (1989) 7768-7771
13. van Mourik J.A., Romani de Wit T., and Voorberg J. Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol 117 (2002) 113-122
14. Ruggeri Z.M. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1 (2003) 1335-1342
15. Mayadas T.N., Johnson R.C., Rayburn H., Hynes R.O., and Wagner D.D. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 74 (1993) 541-554
16. Montalescot G., Philippe F., Ankri A., et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 98 (1998) 294-299
17. Collet J.P., Montalescot G., Vicaut E., et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108 (2003) 391-394
18. Emeis J.J., van den Eijnden-Schrauwen Y., van den Hoogen C.M., de Priester W., Westmuckett A., and Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 139 (1997) 245-256
19. Huber D., Cramer E.M., Kaufmann J.E., et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 99 (2002) 3637-3645
20. Rosnoblet C., Vischer U.M., Gerard R.D., Irminger J.C., Halban P.A., and Kruithof E.K. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells. Arterioscler Thromb Vasc Biol 19 (1999) 1796-1803
21. Datta Y.H., Youssoufian H., Marks P.W., and Ewenstein B.M. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells. Blood 94 (1999) 2696-2703
22. Cleator J.H., Zhu W.Q., Vaughan D.E., and Hamm H.E. Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP. Blood 107 (2006) 2736-2744
23. McCullough P.A., Gibson C.M., Dibattiste P.M., et al. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J Interv Cardiol 17 (2004) 81-86